NuvoBio

A big thank you to Julia Pomoransky (Rintoul), Maura Campbell, and Jose L. Rodriguez for representing NuvoBio at this important meeting!

As 2024 draws to a close, we’re taking a moment to reflect on an incredible year of innovation, collaboration, and achievements at NuvoBio! What an amazing journey it’s been! We’ve collaborated, innovated, and turned aspirations into achievements. Here are just three milestones we’re especially proud of in 2024: 1. Graduating from the Creative Destruction Lab Cancer Stream 2. Becoming a Platinum Pass company with Capital BioVentures 3. Moving into new laboratory space to advance our drug development program None of this would have been possible without our dedicated team, trusted partners, supportive clients, and vibrant community. A heartfelt thank you to everyone who made 2024 such a remarkable year. Here’s to an even brighter 2025—we can’t wait to see what’s ahead!

NuvoBio is excited to announce we are one of the first companies to receive lab space and funding through the Capital BioVentures program! This support will be instrumental in accelerating our research and development efforts. Thank you to CBV and FedDev Ontario for this incredible opportunity. 🥼 🏢 🚀 #peptidetherapeutics #drugdiscovery #funding

Yesterday, we had the privilege of attending the Healthy IP Strategies in Life Sciences & Health Tech workshop hosted by OBio. The event featured an impressive lineup of Ontario’s top #IP experts, including lawyers, patent agents, and industry leaders. 🖊 Workshops like this reinforce that we’re not alone on our journey and highlight the incredible support and collaborative opportunities available for biotech start-ups to foster growth and innovation. 🤝 A huge thank you to the organizers and speakers for creating such an informative and engaging day. Special thanks to OBIO, Carleton University, Capital BioVentures, Invest Ottawa, Intellectual Property Ontario (IPON), and @Elevate IP for making this event a success. 🌟 #Innovation #Biotech #Collaboration #IPStrategies #Peptides #PeptideTherapeutics 

Dive into the future of drug development with NeoPeptix, the first of its kind in combating Cryptococcal Meningitis. Our AI platform has unlocked the potential of targeted therapies, setting a new standard in peptide-based treatments. Biotechnology experts, join us on this journey of innovation and discovery as we revolutionize the way therapeutic solutions are crafted. #NeoPeptix #CryptococcalMeningitis #PrecisionMedicine #PeptideDiscovery #AIDriven #NuvoBio #PharmaceuticalInnovation #DrugDevelopment #Biotechnology #HealthcareRevolution

Last week, NuvoBio had the privilege of attending the MashUP24 event hosted by Capital Angel Network in Ottawa, and what an inspiring experience it was! The energy in the room was electric as we connected with leaders, passionate founders, and investors eager to support innovative companies like ours. 🔍 The Life Sciences panel, moderated by Dr. Maura Campbell, offered invaluable insights into founding and scaling life science companies, further fueling our drive for growth. Special thanks to Suzanne Grant, CD, the organizer, for making this incredible event possible, and to Team Mash for their hard work behind the scenes. It was also great seeing some familiar faces from Carleton’s Innovation Hub and Capital BioVentures! Events like these remind us of the power of community and collaboration in pushing the boundaries of what’s possible. We are immensely grateful to everyone who contributed to this experience, and we look forward to continuing these impactful conversations. 💫 #Innovation #MASH #MASHUP24 #MarketAccess #Networking #NuvoBio #PeptideTherapeutics #Peptides #Investments #Ottawa

Did you know that NuvoBio offers platform services?! 🔊 We utilize our powerful DarwinAI platform, developed for generating our own drug targets, to assist others in their pursuits as well! 🔍 Whether you're in oncology, CAR-T therapy, infectious diseases, anti-microbial research, or much more, our versatile platform delivers outstanding results. Contact us today to learn more about our fee-for-service model and receive your own personalized quote! #NuvoBio #PlatformServices #DarwinAI #Biotechnology #DrugDiscovery #PeptideTherapeutics #Peptides

We are ecstatic to announce that NuvoBio has successfully graduated from the Creative Destruction Lab - Cancer stream! 🎓 🎉 A heartfelt thank you to all our dedicated mentors whose invaluable time and support have been instrumental in our journey to this milestone over the past 9 months. Last week, we had an incredible time at the in-person CDL Super Session in Toronto. It was a fantastic opportunity to connect and learn alongside other innovators from CDL streams across the world! 🌍 #NuvoBio #CDL #CDLAlumni #CancerStream #InfectiousDisease #MilestoneAchievement #PeptideTherapeutics #InnovativeTreatments

Our most exciting post yet! 💫 🔈 NeoPeptix 🔈 - Our Solution to Cryptococcus neoformans In our last post, we highlighted the critical need for innovative solutions to combat Cryptococcus neoformans, the #1 fungal pathogen of concern. If you missed it, be sure to check it out! Over the past few months, we have been rigorously developing our lead candidate, NeoPeptix, as a potential peptide drug against this dangerous fungus. We're thrilled to show you one piece of the puzzle in this post. Check out how NeoPeptix outperforms the current leading treatment, fluconazole. These are nutrient-rich plates showcasing C. neoformans colonies in the presence of NeoPeptix versus fluconazole. Our solution is 40x more potent, with no human cell toxicity or hemolytic activity. 🙌 Next up are animal studies! We are eager to continue de-risking this peptide. Stay tuned for more updates. Together, we can make a difference. 🌍 #HealthcareInnovation #FungalInfections #InfectiousDisease #CryptococcusNeoformans #NuvoBio #MedicalResearch #GlobalHealth #InnovativeTreatments #PublicHealth #PeptideTherapeutics

🌟 Exciting News in the Fight Against Fungal Infections! 🌟 Cryptococcus neoformans has been identified as the number one fungal pathogen of concern by the World Health Organization! This serious pathogen affects over a million people annually, leading to over 600,000 global deaths. The rising prevalence of immunocompromised individuals and increasing resistance to the current primary treatment, fluconazole, intensify the urgency for new solutions. At NuvoBio, we have recognized the critical need for innovative treatments. That’s why we’ve been diligently working on a new treatment option, and we’re thrilled to share that we have some promising results to report! Stay tuned for updates as we continue our mission to combat this devastating pathogen and improve outcomes for patients worldwide. Together, we can make a difference. 🌍 #HealthcareInnovation #FungalInfections #CryptococcusNeoformans #NuvoBio #MedicalResearch #GlobalHealth #InnovativeTreatments #PublicHealth #PeptideTherapeutics